Pathogenic Roles of RNA-Binding Proteins in Sarcomas

Overview

Journal Cancers (Basel)

Publisher MDPI

Specialty Oncology

Date 2022 Aug 12

PMID 35954475

Authors

Yu Hai

Asuka Kawachi

Xiaodong He

Akihide Yoshimi

Affiliations

Soon will be listed here.

Abstract

RNA-binding proteins (RBPs) are proteins that physically and functionally bind to RNA to regulate the RNA metabolism such as alternative splicing, polyadenylation, transport, maintenance of stability, localization, and translation. There is accumulating evidence that dysregulated RBPs play an essential role in the pathogenesis of malignant tumors including a variety of types of sarcomas. On the other hand, prognosis of patients with sarcoma, especially with sarcoma in advanced stages, is very poor, and almost no effective standard treatment has been established for most of types of sarcomas so far, highlighting the urgent need for identifying novel therapeutic targets based on the deep understanding of pathogenesis. Therefore, defining the network of interactions between RBPs and disease-related RNA targets will contribute to a better understanding of sarcomagenesis and identification of a novel therapeutic target for sarcomas.

Citing Articles

Role of the RNA-binding protein family in gynecologic cancers.

Hao L, Zhang J, Liu Z, Zhang Z, Mao T, Guo J Am J Cancer Res. 2023; 13(8):3799-3821.

PMID: 37693158 PMC: 10492115.

Functional Role of RBP in Osteosarcoma: Regulatory Mechanism and Clinical Therapy.

Que Z, Yang K, Wang N, Li S, Li T Anal Cell Pathol (Amst). 2023; 2023:9849719.

PMID: 37426488 PMC: 10328736. DOI: 10.1155/2023/9849719.

Extracellular vesicle-associated IGF2BP3 tunes Ewing sarcoma cell migration and affects PI3K/Akt pathway in neighboring cells.

Mancarella C, Giusti V, Caldoni G, Laginestra M, Parra A, Toracchio L Cancer Gene Ther. 2023; 30(9):1285-1295.

PMID: 37353558 PMC: 10501906. DOI: 10.1038/s41417-023-00637-8.

References

Forrest A, Kawaji H, Rehli M, Baillie J, de Hoon M, Haberle V . A promoter-level mammalian expression atlas. Nature. 2014; 507(7493):462-70. PMC: 4529748. DOI: 10.1038/nature13182. View

Seiler M, Peng S, Agrawal A, Palacino J, Teng T, Zhu P . Somatic Mutational Landscape of Splicing Factor Genes and Their Functional Consequences across 33 Cancer Types. Cell Rep. 2018; 23(1):282-296.e4. PMC: 5933844. DOI: 10.1016/j.celrep.2018.01.088. View

Vibert J, Saulnier O, Collin C, Petit F, Borgman K, Vigneau J . Oncogenic chimeric transcription factors drive tumor-specific transcription, processing, and translation of silent genomic regions. Mol Cell. 2022; 82(13):2458-2471.e9. DOI: 10.1016/j.molcel.2022.04.019. View

Hu X, Zhang C, Zhang Y, Hong C, Chen W, Shen W . Down regulation of human positive coactivator 4 suppress tumorigenesis and lung metastasis of osteosarcoma. Oncotarget. 2017; 8(32):53210-53225. PMC: 5581104. DOI: 10.18632/oncotarget.18290. View

Hentze M, Castello A, Schwarzl T, Preiss T . A brave new world of RNA-binding proteins. Nat Rev Mol Cell Biol. 2018; 19(5):327-341. DOI: 10.1038/nrm.2017.130. View

Grossi E, Raimondi I, Goni E, Gonzalez J, Marchese F, Chapaprieta V . A lncRNA-SWI/SNF complex crosstalk controls transcriptional activation at specific promoter regions. Nat Commun. 2020; 11(1):936. PMC: 7028943. DOI: 10.1038/s41467-020-14623-3. View

Selvanathan S, Graham G, Grego A, Baker T, Hogg J, Simpson M . EWS-FLI1 modulated alternative splicing of ARID1A reveals novel oncogenic function through the BAF complex. Nucleic Acids Res. 2019; 47(18):9619-9636. PMC: 6765149. DOI: 10.1093/nar/gkz699. View

Jerby-Arnon L, Neftel C, Shore M, Weisman H, Mathewson N, McBride M . Opposing immune and genetic mechanisms shape oncogenic programs in synovial sarcoma. Nat Med. 2021; 27(2):289-300. PMC: 8817899. DOI: 10.1038/s41591-020-01212-6. View

Obeng E, Chappell R, Seiler M, Chen M, Campagna D, Schmidt P . Physiologic Expression of Sf3b1(K700E) Causes Impaired Erythropoiesis, Aberrant Splicing, and Sensitivity to Therapeutic Spliceosome Modulation. Cancer Cell. 2016; 30(3):404-417. PMC: 5023069. DOI: 10.1016/j.ccell.2016.08.006. View

10.

Liu M, Fu X, Jiang L, Ma J, Zheng X, Wang S . Colon cancer cells secreted CXCL11 via RBP-Jκ to facilitated tumour-associated macrophage-induced cancer metastasis. J Cell Mol Med. 2021; 25(22):10575-10590. PMC: 8581314. DOI: 10.1111/jcmm.16989. View

11.

Wang E, Lu S, Pastore A, Chen X, Imig J, Chun-Wei Lee S . Targeting an RNA-Binding Protein Network in Acute Myeloid Leukemia. Cancer Cell. 2019; 35(3):369-384.e7. PMC: 6424627. DOI: 10.1016/j.ccell.2019.01.010. View

12.

Suter B . RNA localization and transport. Biochim Biophys Acta Gene Regul Mech. 2018; 1861(10):938-951. DOI: 10.1016/j.bbagrm.2018.08.004. View

13.

Chu J, Cargnello M, Topisirovic I, Pelletier J . Translation Initiation Factors: Reprogramming Protein Synthesis in Cancer. Trends Cell Biol. 2016; 26(12):918-933. DOI: 10.1016/j.tcb.2016.06.005. View

14.

Kim E, Ilagan J, Liang Y, Daubner G, Lee S, Ramakrishnan A . SRSF2 Mutations Contribute to Myelodysplasia by Mutant-Specific Effects on Exon Recognition. Cancer Cell. 2015; 27(5):617-30. PMC: 4429920. DOI: 10.1016/j.ccell.2015.04.006. View

15.

van Dijk E, Le Hir H, Seraphin B . DcpS can act in the 5'-3' mRNA decay pathway in addition to the 3'-5' pathway. Proc Natl Acad Sci U S A. 2003; 100(21):12081-6. PMC: 218716. DOI: 10.1073/pnas.1635192100. View

16.

Panagopoulos I, Mencinger M, Dietrich C, Bjerkehagen B, Saeter G, Mertens F . Fusion of the RBP56 and CHN genes in extraskeletal myxoid chondrosarcomas with translocation t(9;17)(q22;q11). Oncogene. 1999; 18(52):7594-8. DOI: 10.1038/sj.onc.1203155. View

17.

Wang X, Penalva L, Yuan H, Linnoila R, Lu J, Okano H . Musashi1 regulates breast tumor cell proliferation and is a prognostic indicator of poor survival. Mol Cancer. 2010; 9:221. PMC: 2939568. DOI: 10.1186/1476-4598-9-221. View

18.

Martins A, Olmos D, Missiaglia E, Shipley J . Targeting the insulin-like growth factor pathway in rhabdomyosarcomas: rationale and future perspectives. Sarcoma. 2011; 2011:209736. PMC: 3061277. DOI: 10.1155/2011/209736. View

19.

Shirai C, Ley J, White B, Kim S, Tibbitts J, Shao J . Mutant U2AF1 Expression Alters Hematopoiesis and Pre-mRNA Splicing In Vivo. Cancer Cell. 2015; 27(5):631-43. PMC: 4430854. DOI: 10.1016/j.ccell.2015.04.008. View

20.

Arndt C, Stoner J, Hawkins D, Rodeberg D, Hayes-Jordan A, Paidas C . Vincristine, actinomycin, and cyclophosphamide compared with vincristine, actinomycin, and cyclophosphamide alternating with vincristine, topotecan, and cyclophosphamide for intermediate-risk rhabdomyosarcoma: children's oncology group study D9803. J Clin Oncol. 2009; 27(31):5182-8. PMC: 2773476. DOI: 10.1200/JCO.2009.22.3768. View